Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Metformin monotherapy for adults with type 2 diabetes mellitus

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Lawrence A Leiter
  • Stephen C Bain
  • Irene Hramiak
  • Esteban Jódar
  • Sten Madsbad
  • Theis Gondolf
  • Thomas Hansen
  • Ingrid Holst
  • Ildiko Lingvay
Vis graf over relationer

BACKGROUND: The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0 mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in subjects with type 2 diabetes (T2D) and high CV risk. The effects of gender, age and baseline CV risk on outcomes are important considerations for further study.

METHODS: Subjects were grouped according to gender, age (50-65 years and > 65 years), and CV risk profile at baseline (prior myocardial infarction [MI] or stroke vs no prior MI or stroke, and established CV disease [CVD] vs CV risk factors alone, including subjects with chronic kidney disease). Time to MACE and its individual components (CV death, nonfatal MI, nonfatal stroke), hospitalization for unstable angina or heart failure, and revascularization (coronary and peripheral) were analyzed for all subgroups. Additional analyses were performed for gender and age to investigate change from baseline in HbA1c and body weight, as well as tolerability.

RESULTS: A total of 3297 subjects were included. The majority of subjects (60.7%) were male; 43% were > 65 years of age; 41.5% had a history of MI or stroke; and 76.8% had established CVD. Compared with placebo, semaglutide reduced the risk of the first occurrence of MACE and each MACE component consistently across all subgroups (gender, age, and baseline CV risk profile). Revascularizations, HbA1c and body weight were also reduced consistently across all subgroups compared with placebo. Gastrointestinal adverse events in all treatment groups were more common among women than men, but rates of premature treatment discontinuation were similar for both genders.

CONCLUSIONS: In this post hoc analysis of SUSTAIN 6, once-weekly semaglutide vs placebo reduced the risk of MACE in all subjects included in the trial, regardless of gender, age, or baseline CV risk profile. Trial registry, Identifying number: NCT01720446, Date of registration: October 29, 2012.

TidsskriftCardiovascular Diabetology
Udgave nummer1
StatusUdgivet - 6 jun. 2019

ID: 57329216